AKT1 and breast cancer: Next, we investigated the clinical relevance of higher levels of p-AKT in MCF-7 and ZR-75-1 breast cancer cells resistant to fulvestrant (Fig. 2F) and combined fulvestrant and CDK4/6i (MPF-R cells) (Fig. 5E).